Cargando…

Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care

BACKGROUND: Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. STUDY QUESTION: What is the effectiveness of rivaroxaban versus the standard of care (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peacock, W. Frank, Coleman, Craig I., Wells, Phil, Fermann, Gregory J., Wang, Li, Baser, Onur, Schein, Jeff, Crivera, Concetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2019
Materias:	Cardiovascular Conditions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299482/ https://www.ncbi.nlm.nih.gov/pubmed/32685588 http://dx.doi.org/10.36469/9936

Ejemplares similares

Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism
por: Wang, Li, et al.
Publicado: (2019)

Benefit of early discharge among patients with low-risk pulmonary embolism
por: Wang, Li, et al.
Publicado: (2017)

Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation
por: Wang, Li, et al.
Publicado: (2013)

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2016)

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain
por: Granero Xiberta, Xavier, et al.
Publicado: (2016)

External validation of a multivariable claims-based rule for predicting in-hospital mortality and 30-day post-pulmonary embolism complications
por: Coleman, Craig I., et al.
Publicado: (2016)

Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis
por: Nguyen, Elaine, et al.
Publicado: (2017)

External validation of prognostic rules for early post-pulmonary embolism mortality: assessment of a claims-based and three clinical-based approaches
por: Weeda, Erin R., et al.
Publicado: (2016)

The Association of Economic Outcome and Geriatric Syndromes among Older Adults with Transcatheter Aortic Valve Replacement (TAVR)
por: Kwak, Min Ji, et al.
Publicado: (2020)

Validation of the multivariable In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule within an all-payer inpatient administrative claims database
por: Coleman, Craig I, et al.
Publicado: (2015)

Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective
por: Khaykin, Yaariv, et al.
Publicado: (2016)

Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis
por: Han, Xue, et al.
Publicado: (2022)

Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing
por: Diel, Roland, et al.
Publicado: (2019)

An Algorithm to Analyze Cost Heterogeneity using Counterfactual Scenarios in Endovascular versus Open Repair of Abdominal Aortic Aneurysm: Predicting Costs for Subsequent Patients
por: Jones, Christopher A., et al.
Publicado: (2014)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
por: Margolis, Jay M., et al.
Publicado: (2016)

Effects of Pimobendan on Prolonging Time to Rehospitalization or Frequency of Rehospitalization in Patients with Heart Failure: A Retrospective Cohort Study Using a Medical Administrative Database (PREFER Study)
por: Kodama, Kazuhisa, et al.
Publicado: (2020)

A Systematic Literature Review of Three Stenting Strategies for Bifurcation Lesions in Coronary Artery Disease
por: Parsley-Raines, Larragem, et al.
Publicado: (2019)

Sternal-Wound Infections following Coronary Artery Bypass Graft: Could Implementing Value-Based Purchasing be Beneficial?
por: Brandt, Dominique, et al.
Publicado: (2020)

Real-world Bleeding Outcomes and Costs Following Vascular Graft Anastomosis Using PROLENE Sutures with HEMO-SEAL Technology in Patients Undergoing Abdominal Aortic Aneurysm Repair
por: Sutton, Nadia Y., et al.
Publicado: (2017)

The Effects of Catheter Ablation Therapy on Medication Use and Expenditures in Patients with Atrial Fibrillation
por: Reynolds, Matthew R., et al.
Publicado: (2014)

The Cost Effectiveness of Hand Held Ultrasound Scanning for Abdominal Aortic Aneurysm in Older Males with a History of Smoking
por: Phiri, Denver, et al.
Publicado: (2013)

Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
por: Berger, Ariel, et al.
Publicado: (2014)

The Cost of an Operating Room Minute for Heart Valve Procedures
por: Grossi, Eugene A., et al.
Publicado: (2015)

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
por: Ruiz, George, et al.
Publicado: (2018)

The Association of COPD Exacerbations with New Onset Type 2 Diabetes among Medicare Patients
por: Marino, Joseph S., et al.
Publicado: (2017)

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
por: Song, Ci, et al.
Publicado: (2022)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
por: Aguiar, Carlos, et al.
Publicado: (2022)

Cardiovascular Disease and Its Implication for Higher Catastrophic Health Expenditures Among Households in Sub-Saharan Africa
por: Adeniji, Folashayo Ikenna Peter, et al.
Publicado: (2023)

One-year Prevalence, Comorbidities, and Cost of Hospitalizations for Alpha-1 Antitrypsin Deficiency among Patients with Chronic Obstructive Pulmonary Disease in the United States
por: Blanchette, Christopher M., et al.
Publicado: (2017)

New Oral Anaticoagulant Prescribing Decisions amongst General Practitioners: Handle with Care
por: Kirby, Ann, et al.
Publicado: (2017)

Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients: Describing the Diagnostic Odyssey
por: Arnold, Renée JG, et al.
Publicado: (2015)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Japanese Patients’ and Physicians’ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment
por: Okumura, Ken, et al.
Publicado: (2015)

A Retrospective Claims-Based Study Evaluating Clinical and Economic Burden Among Patients With Moderate to Severe Osteoarthritis Pain in the United States
por: Schepman, Patricia B., et al.
Publicado: (2022)

Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study
por: Fermann, Gregory J, et al.
Publicado: (2015)

The 500-year Cultural & Economic Trajectory of Tobacco: A Circle Complete
por: Jones, Christopher A., et al.
Publicado: (2017)

Assessing the Economic Burden and Benefit-cost of Treating Attention-deficit Hyperactivity Disorder in Germany
por: Kotsopoulos, Nikolaos, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_03kanu43grf6f7frbrlsh1c3qo